Precision Path:
What our architecture builds
We built Precision Path on our own architecture to show what research-grade oncology CDS actually looks like. Three tumor types. 160+ pathway steps. 7,000+ computed survival baselines. It exists to demonstrate what we can build for your specific asset.
The problem worth solving
Your drug is approved. The eligible population is defined. So why isn't uptake tracking to your forecast?
The grey zone between guidelines and decisions
Oncologists understand guidelines broadly. What they struggle with is applying them to the specific patient in front of them: genomic risk that cuts across anatomic risk, partial treatment courses, competing comorbidities. Guidelines don't resolve those questions.
No numbers to hold onto
Physicians want to give patients something concrete. Instead they offer qualitative statements: "the trial showed benefit, and your situation is probably better than average." That's not satisfying for anyone in the room.
Approval doesn't drive behavior
The evidence that persuades a regulator isn't always what moves a community oncologist at 4pm on a Friday. Real-world uptake requires tools that work at the point of decision, not just in the label.
The architecture, in three steps
This is what our CDS pipeline produces: a structured clinical picture, run through an evidence engine, and returned as a personalized pathway that supports the decision a physician actually needs to make.
Structured Clinical Intake
Tumour characteristics, staging, receptor status, and genomic test results. Everything systematically captured in a comprehensive clinical profile.
Real-Time Evidence Engine
The patient's profile is matched against baseline NCCN 2026 guidelines, and then explicitly quantified using genomic signatures and published clinical trial outcomes.
Clear Treatment Pathways
A structured, step-by-step treatment pathway with survival projections, benefit analyses, and side effect management. Equipping care teams for shared decision-making.
Everything you need in one place
Database Twin Architecture
The engine simultaneously powers two distinct experiences from a single source of truth (SSOT). Clinicians receive high-fidelity NCCN/ESMO data, while patients receive a 6th-grade reading level translation, ensuring shared decision-making without compromising clinical rigor.
Quantifiable Survival Projections
We compute and visualize over 7,000 potential Kaplan-Meier survival curves, personalized to the patient's exact clinical profile, plotting 5-year and 10-year baseline outcomes.
Beyond Static Guidelines
NCCN 2026 is our baseline, not our ceiling. We map 25+ distinct clinical pathways and 160+ steps with real-time probabilistic outcomes.
Dynamic Marginal Benefit Calculation
Stop guessing at treatment efficacy. Our computational engine calculates the exact survival benefit of every intervention in real time, showing precisely how much value a specific drug adds to a patient's long-term prognosis.
Integrative Medicine
Evidence-graded complementary therapies (yoga, acupuncture, mindfulness) integrated alongside conventional treatments with safety interactions noted.
Side Effect Tracking
Comprehensive side effect profiles for every treatment, with proactive management strategies and when to seek urgent care.
Multi-Tumor Deployment
Breast Cancer
NCCN 2026-aligned decision support modeling 147 pathway steps, 19 distinct pathways, and over 6,900 survival curves.
- Native integration with MammaPrint/BluePrint
- Exact marginal benefit quantification
- T1mi microinvasive & premenopausal OFS ladders
Precision Path: GIST
Extending the core architecture to Gastrointestinal Stromal Tumors, featuring automated literature surveillance and advanced toxicity management.
- Integrative Medicine & Toxicity Modules
- Automated Literature Surveillance Agents
- Neoadjuvant and Adjuvant KIT/PDGFRA pathways
Precision Path: Kidney
The newest module in our Decision OS, bringing sharp focus to personalization and accuracy in settings where the adjuvant decision is critical.
- High-stakes adjuvant decision support
- Advanced State Management capabilities
- Fully unified Core OS architecture
Interested in what this could look like for your asset?
If you're a pharma or diagnostics company thinking about real-world uptake, we'd welcome the conversation. Precision Path is the proof of concept. Your asset is the next step.
Stay in the loop
New thinking on oncology decision-making, health technology, and clinical strategy. No schedule, no noise — just when there's something worth sharing.